Filtered By:
Condition: Atrial Fibrillation
Countries: Taiwan Health

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 189 results found since Jan 2013.

Renal Function Estimates and Dosing of Direct Oral Anticoagulants in Stroke Patients with Atrial Fibrillation: An Observational Study.
CONCLUSION: Although substituting eGFR for CrCl carries potential risks of DOAC overdosing in patients with AF, the effect might be offset by clinicians' predilection for lower dosage in this stroke cohort. PMID: 31304571 [PubMed - in process]
Source: Acta Neurologica Taiwanica - July 17, 2019 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research

Patients with periodontitis are at a higher risk of stroke: A Taiwanese cohort study
CONCLUSION: Therefore, this study suggests a high risk of stroke in patients with periodontitis.PMID:36000972 | DOI:10.1097/JCMA.0000000000000797
Source: Atherosclerosis - August 24, 2022 Category: Cardiology Authors: Pei-Wei Hsu Yen-Wen Shen Syamsiah Syam Wen-Miin Liang Trong-Neng Wu Jui-Ting Hsu Lih-Jyh Fuh Source Type: research

Functional outcome prediction of ischemic stroke patients with atrial fibrillation accepting post-acute care training
ConclusionIn the current study, nearly half of the enrolled patients showed favorable functional recovery. The outcome assessments seem to correlate well with NIHSS and Barthel Index scores, rather than mRS. The anxiety/depression and usual activities domains of the EQ-5D results are associated with and have a great impact after the patients undertake the PAC rehabilitative strategy. Moreover, the variables obtained through carotid duplex and plaque index might also play a significant role in determining the patient's functional outcome.
Source: Frontiers in Neurology - September 23, 2022 Category: Neurology Source Type: research

Monotherapy of aspirin or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study.
CONCLUSIONS: Warfarin is suggested to be prescribed in preventing ischemic stroke for low-stroke-risk atrial fibrillation patients with hypertension and hyperlipidemia. PMID: 29718533 [PubMed - as supplied by publisher]
Source: Cardiology Journal - May 2, 2018 Category: Cardiology Authors: Liu CY, Chen HC Tags: Cardiol J Source Type: research

Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation
In conclusion, more and more patients who suffer a hematuria while on oral anticoagulant therapy resume NOAC. Patients resuming NOAC have similar risks of ischemic stroke/systemic embolism and major bleeding compared with those resuming VKA.
Source: Journal of Thrombosis and Thrombolysis - May 13, 2020 Category: Hematology Source Type: research

Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
ConclusionsApixaban was more cost effective than warfarin, dabigatran, and rivaroxaban for stroke prevention in patients with AF. Among the anticoagulant therapies, the WTP threshold of apixaban was about US$50,000 per QALY gained. These cost-effectiveness estimations provide useful information to aid clinical decision making in stroke prevention for AF patients.
Source: Clinical Drug Investigation - December 16, 2016 Category: Drugs & Pharmacology Source Type: research

Antithrombotic Treatment May Reduce Mortality Among New-Onset Atrial Fibrillation Patients with Gray-Zone Risk of Stroke.
This study aimed to evaluate whether gray zone AF patients could benefit from reduced all-cause mortality under antithrombotic treatment. This was a longitudinal cohort study performed using data from claim forms submitted to the Taiwan Bureau of National Health Insurance from January 2000 to December 2011. The new-onset AF patients consisted of a gray zone cohort with a total of 1237 patients being enrolled. The primary outcome was all-cause mortality between 2001 and 2011. Patients in the gray zone receiving antithrombotic treatment had a significant reduction in all-cause mortality [hazard ratio (HR): 0.21; 95% confiden...
Source: International Heart Journal - February 13, 2019 Category: Cardiology Tags: Int Heart J Source Type: research

Stroke Risk Should Be Reassessed Annually in A-Fib Stroke Risk Should Be Reassessed Annually in A-Fib
The risk of stroke should be reassessed annually in patients with atrial fibrillation (AF), because CHA2DS2-VASc scores used to determine the need for anticoagulation commonly rise over time, researchers from Taiwan report.Reuters Health Information
Source: Medscape Medical News Headlines - January 4, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3 –4.5 h
ConclusionIn the 34.5-h time window, the effectiveness and safety of standard-dose and low-dose alteplase may be comparable. A standard dose may be selected for patients with cardioembolism, atrial fibrillation, or hypercholesterolemia.
Source: Frontiers in Neurology - February 8, 2022 Category: Neurology Source Type: research

New-Onset Atrial Fibrillation Is a Risk Factor of Ischemic Stroke in Chronic Obstructive Pulmonary Disease
In conclusion, COPD patients suffering from new-onset AF had an increased incidence of IS in the population observation study. New-onset AF was an omit risk factor for IS in COPD in the Chinese population.PMID:35206997 | DOI:10.3390/healthcare10020381
Source: Atherosclerosis - February 25, 2022 Category: Cardiology Authors: Chi-Chun Liu Yu-Hsuan Chen Yin-Han Chang Wu-Chien Chien Hui-Chen Lin Chun-Gu Cheng Chun-An Cheng Source Type: research

Early rhythm control and the risks of ischaemic stroke, heart failure, mortality and adverse events when performed early ( & lt;3 months)
CONCLUSIONS: Early rhythm control, especially when performed earlier (<3months), was associated with a lower risk of adverse events than usual care among patients with early AF.PMID:35322396 | DOI:10.1055/a-1807-0336
Source: Thrombosis and Haemostasis - March 24, 2022 Category: Hematology Authors: Tze-Fan Chao Yi-Hsin Chan Chern-En Chiang Ta-Chuan Tuan Jo-Nan Liao Tzeng-Ji Chen Gregory Yh Lip Shih-Ann Chen Source Type: research

XaMINA: A Real-World, Prospective, Observational Study of Treatment-Na ïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia
CONCLUSION: XaMINA demonstrated low incidence rates of major bleeding events and thromboembolic events in patients with NVAF newly initiating rivaroxaban in South Korea and Taiwan, consistent with previous real-world studies reconfirming the results of the ROCKET AF study.TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov (identifier NCT03284762) on 15 September 2017.PMID:35616848 | DOI:10.1007/s12325-022-02102-8
Source: Adv Data - May 26, 2022 Category: Epidemiology Authors: Ping-Yen Liu Eue-Keun Choi Tae-Seok Kim Jen-Yuan Kuo Jung Myung Lee Young Keun On Sang-Weon Park Hyung-Wook Park Dong-Gu Shin Lili Wang Hsueh-Wei Yen Moon-Hyoung Lee XaMINA Investigators Source Type: research